Omrix, as you know are conducting a trial for a fibrin pad, which at a selling point of $500 will enter the market 2008 with US unit sales of 20,853 capturing 20% of the market share (according to the 2005 un-updated report at Omrix website, link below). This is expected to grow to a peak of 70% of the market by 2013.
While EMS and military use is apparently not the main focus for sales, it appears the US market is the main target further aimed at "less price sensitive" surgeons.
I am sure Ethicon must be preparing for a mighty unveiling and market entry, still one wonders whats going on with this talk of J&J woundcare sale? For Ethicon the Fibrin pad is probably a good strategy for moving some of that human sourced Evithrom (another Omrix thrombin product). As the recently funded $100 million for Zymogenetics with their recombinant product recothrom hits the stage.
Patch revenues are estimated to total over half a billion dollars within 10 years of launch. Further figures mentioned estimate the European market at 50% of the US and the ROW at 45% of the US market. Similar growth is anticipated in Europe and ROW as Stateside.
The full Pdf is available at the Omrix site or HERE is a link.
